Read by QxMD icon Read


Zelie Guitton, Louis Terriou, Jean-Christophe Lega, Raphaele Nove-Josserand, Miguel Hie, Zahir Amoura, James B Bussel, Mohamed Hamidou, Eric Rosenthal, Bertrand Lioger, Dominique Chauveau, Axel Chaminade, Nadine Magy-Bertrand, Marc Michel, Sylvain Audia, Bertrand Godeau, Matthieu Mahevas
Objectives: The use of thrombopoietin-receptor agonists (TPO-RAs) has increased as a second-line therapy in ITP, but the efficacy and safety of such drugs has not been evaluated in SLE-associated ITP. Methods: This was a multicentre retrospective cohort study from 2009 to 2016. Participating centres (n = 11) were secondary- or tertiary-care hospitals belonging to the French national network for adult ITP. Results: We included 18 patients with SLE-ITP treated with TPO-RAs; 10 (55%) had aPL, 5 (27%) showing definite APS...
May 10, 2018: Rheumatology
Peter Heeringa, Mark Alan Little
No abstract text is available yet for this article.
May 10, 2018: Rheumatology
Gamal Chehab, Jutta G Richter, Ralph Brinks, Rebecca Fischer-Betz, Borgi Winkler-Rohlfing, Matthias Schneider
Objectives: Vaccinations are an important measure to prevent infections in immunocompromised patients. The knowledge of vaccination coverage and reasons for non-vaccination in patients with SLE is scarce. The aim of this study was to assess coverage rates of selected vaccinations in a representative sample of SLE patients and to identify predictors for non-vaccination. Methods: In 2013, information on selected vaccinations (coverage, application and reservations) and on demographics, clinical parameters and health beliefs was assessed by means of a self-reported questionnaire among a representative sample of SLE patients in Germany (LuLa cohort)...
May 10, 2018: Rheumatology
Mark C Genovese, Janet van Adelsberg, Chunpeng Fan, Neil M H Graham, Hubert van Hoogstraten, Janie Parrino, Erin K Mangan, Alberto Spindler, Tom W J Huizinga, Désirée van der Heijde
Objectives: To examine 2-year safety, efficacy and radiographic outcomes of sarilumab in adults with RA and inadequate response to MTX (MTX-IR). Methods: In the randomized, placebo-controlled MOBILITY trial, MTX-IR patients received subcutaneous sarilumab (150 or 200 mg) or placebo every 2 weeks (q2w) plus MTX for up to 1 year. Upon study completion, patients could enrol in the open-label, long-term extension study (EXTEND, NCT011046652), in which all patients received sarilumab 200 mg q2w plus MTX...
May 9, 2018: Rheumatology
Julia Steinberg, Roger A Brooks, Lorraine Southam, Sahir Bhatnagar, Theodoros I Roumeliotis, Konstantinos Hatzikotoulas, Eleni Zengini, J Mark Wilkinson, Jyoti S Choudhary, Andrew W McCaskie, Eleftheria Zeggini
Objectives: To identify molecular differences between chondrocytes from osteophytic and articular cartilage tissue from OA patients. Methods: We investigated genes and pathways by combining genome-wide DNA methylation, RNA sequencing and quantitative proteomics in isolated primary chondrocytes from the cartilaginous layer of osteophytes and matched areas of low- and high-grade articular cartilage across nine patients with OA undergoing hip replacement surgery. Results: Chondrocytes from osteophytic cartilage showed widespread differences to low-grade articular cartilage chondrocytes...
May 8, 2018: Rheumatology
Sibel Bakirci Ureyen, Cengiz Karacaer, Bilal Toka, Zeynep Erturk, Ahmet Tarik Eminler, Muhammed Kaya, Koray Tascilar, Ali Tamer, Ihsan Uslan, Esra Kurum, Dennis McGonagle, Sibel Zehra Aydin
Objective: Higher subclinical enthesitis on US has been reported in IBD and celiac disease, separately. The objective of this study was to compare IBD and celiac disease for enthesitis on US. Higher enthesitis scores in IBD compared with celiac disease would support a shared pathogenic mechanism between IBD and spondyloarthritis, whereas similar scores may suggest a general impact of gut inflammation on the enthesis. Methods: Patients with IBD, celiac disease and healthy controls (HCs) were recruited and 12 entheses were scanned by US, blind to the diagnosis and clinical assessment...
May 8, 2018: Rheumatology
Tommaso Schioppo, Annalisa Orenti, Patrizia Boracchi, Orazio De Lucia, Antonella Murgo, Francesca Ingegnoli
Objectives: I.v. iloprost (ILO) may be used in the treatment of refractory RP and digital ulcers. We aim to evaluate the acute and chronic effects of two different ILO regimens by power Doppler US (PDUS) and nailfold videocapillaroscopy. Methods: In this 3-month single-centre pragmatic non-randomized trial, 96 SSc patients were included and stratified according to ILO treatment as: no ILO (group A), ILO once monthly (group B) and ILO for five consecutive days (group C)...
May 3, 2018: Rheumatology
Xavier Puéchal, Michele Iudici, Ana Luisa Calich, Alexandre Vivot, Benjamin Terrier, Alexis Régent, Pascal Cohen, Claire Le Jeunne, Luc Mouthon, Philippe Ravaud, Loïc Guillevin
Objectives: To assess efficacy and safety of rituximab (RTX) induction and maintenance therapy for granulomatosis with polyangiitis (GPA) in a single-centre cohort study. Methods: All patients with active GPA, not enrolled in trials, who received ⩾1 RTX infusion(s) for induction were included. At remission, protocolized maintenance RTX infusions were given every 6 months for 18 months. Kaplan-Meier curves were used to estimate survival rates. Univariable analyses identified factors associated with remission failure and relapse, and Cox models retained independent predictors of relapse...
May 2, 2018: Rheumatology
Marion Delplanque, Marc Gatfosse, Hafid Ait-Oufella, Olaf Mercier, Laurent Savale, Olivier Fain, Arsene Mekinian
No abstract text is available yet for this article.
April 30, 2018: Rheumatology
Hermann Girschick, Martina Finetti, Francesca Orlando, Susanne Schalm, Antonella Insalaco, Gerd Ganser, Susan Nielsen, Troels Herlin, Isabelle Koné-Paut, Silvana Martino, Marco Cattalini, Jordi Anton, Sulaiman Mohammed Al-Mayouf, Michael Hofer, Pierre Quartier, Christina Boros, Jasmin Kuemmerle-Deschner, Denise Pires Marafon, Maria Alessio, Tobias Schwarz, Nicolino Ruperto, Alberto Martini, Annette Jansson, Marco Gattorno
No abstract text is available yet for this article.
April 30, 2018: Rheumatology
Evangelia Zampeli, Haralampos M Moutsopoulos
No abstract text is available yet for this article.
April 30, 2018: Rheumatology
Christopher Sjöwall, Thomas Mandl, Lillemor Skattum, Martin Olsson, Aladdin J Mohammad
Objectives: The aim was to describe the clinical characteristics and epidemiology of hypocomplementaemic urticarial vasculitis (HUV; anti-C1q vasculitis) in two geographically defined areas of Sweden. Methods: In the health-care districts surrounding Skåne University Hospital (mean population 950 560) and Linköping University Hospital (mean population 428 503), all incident cases of HUV residing within the study areas at the onset of disease were identified during the years 2000-15...
April 30, 2018: Rheumatology
Zeeshan Khan, Srishti Gupta, Amit Jaiswal
No abstract text is available yet for this article.
April 30, 2018: Rheumatology
Manoj Pawar, Vijay Zawar
No abstract text is available yet for this article.
April 27, 2018: Rheumatology
(no author information available yet)
No abstract text is available yet for this article.
April 26, 2018: Rheumatology
Walter P Maksymowych, Désirée van der Heijde, Xenofon Baraliakos, Atul Deodhar, Sarah P Sherlock, David Li, Dona Fleishaker, Thijs Hendrikx, Keith S Kanik
Objectives: Minimally important changes (MICs) for SPondyloArthritis Research Consortium of Canada (SPARCC) MRI scores are ⩾2.5 for SI joint and ⩾5 for spine. This post hoc analysis assessed achievement of MIC in SPARCC scores in biologic-naïve patients with AS treated with tofacitinib or placebo, and correlation with clinical responses. Methods: Adult AS patients in a 12-week phase 2 study (n = 207) were randomized 1: 1: 1: 1 to tofacitinib 2, 5 or 10 mg twice daily (BID) or placebo...
April 26, 2018: Rheumatology
Laura Hanns, Lis Cordingley, James Galloway, Sam Norton, Livia A Carvalho, Deborah Christie, Debajit Sen, Roberto Carrasco, Amir Rashid, Helen Foster, Eileen Baildam, Alice Chieng, Joyce Davidson, Lucy R Wedderburn, Kimme Hyrich, Wendy Thomson, Yiannis Ioannou
Objectives: To determine if depressive symptoms assessed near diagnosis associate with future measures of pain, disability and disease for adolescent patients diagnosed with JIA. Methods: Data were analysed from JIA patients aged 11-16 years recruited to the Childhood Arthritis Prospective Study, a UK-based inception cohort of childhood-onset arthritis. Depressive symptoms (using the Mood and Feelings Questionnaire; MFQ), active and limited joint count, disability score (Childhood Health Assessment Questionnaire), pain visual analogue scale and patient's general evaluation visual analogue scale were collected...
April 25, 2018: Rheumatology
Francesco Ciccia, Angelo Ferrante, Giuliana Guggino, Alberto Cavazza, Carlo Salvarani, Aroldo Rizzo
Objective: To evaluate whether CD3 staining performed routinely on temporal artery biopsy specimens might improve the sensitivity of temporal artery biopsy in patients with biopsy-negative GCA. Methods: Two hundred and seventy biopsies were considered for this study, stained with haematoxylin and eosin and with an anti-CD3 antibody. Results: The addition of CD3 staining modified the sensibility and the specificity of the histologic examination in 89...
April 25, 2018: Rheumatology
Ortal Danino, Shuli Svetitsky, Sarah Kenigsberg, Asaf Levin, Shani Journo, Aviram Gold, Michael Drexler, Nimrod Snir, Ori Elkayam, Bilha Fischer, Uri Arad
Objectives: Calcium pyrophosphate deposition (CPPD) is associated with osteoarthritis and is the cause of a common inflammatory articular disease. Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (eNPP1) is the major ecto-pyrophosphatase in chondrocytes and cartilage-derived matrix vesicles (MVs). Thus, eNPP1 is a principle contributor to extracellular pyrophosphate levels and a potential target for interventions aimed at preventing CPPD. Recently, we synthesized and described a novel eNPP1-specific inhibitor, SK4A, and we set out to evaluate whether this inhibitor attenuates nucleotide pyrophosphatase activity in human OA cartilage...
April 24, 2018: Rheumatology
Marwan Bukhari
No abstract text is available yet for this article.
April 20, 2018: Rheumatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"